BioSpace News Archive

Deciphera Pharmaceuticals, Inc. announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022 at 4:20 PM ET in Miami.

Biomind Labs Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression.

AIM ImmunoTech Inc. announced today that data from the ongoing Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen®.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the company will make seven oral presentations at the upcoming American Association for Cancer Research Annual Meeting 2022 being held April 8-13, 2022 in New Orleans, Louisiana.

ZYUS Life Sciences Inc., a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced that the company’s Canadian manufacturing facility has been awarded EU-Good Manufacturing Practice certification.

As part of the collaboration, insitro will deploy its machine-learning capabilities on Genomics England’s histopathology images and accompanying genetic data to learn a multimodal representation that captures the fine grained semantic structure in this high-dimensional clinical data.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that the first patient was dosed in its Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for the treatment of hemophilia B.

Genenta Science will present clinical data from its Phase 1/2a dose-escalation study of its clinical-stage candidate Temferon™ in patients with glioblastoma multiforme (GBM) who have an unmthylated MGMT gene promotor (uMGMT-GBM) at the annual meeting of the American Association for Cancer Research.

Sensus Healthcare, Inc. announces that its Board of Directors has authorized a program to purchase up to $3,000,000 of shares of its Common Stock.

Dyve Biosciences, Inc., a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, announced that Ryan Beal, M.D., Chief Executive Officer and Co-founder, will be participating in a fireside chat at the 34th Annual Roth Conference in Dana Point, California March 13 - 15, 2022.